Development of N-hydroxycinnamamide-based histone deacetylase inhibitors with an indole-containing Cap group

ACS Medicinal Chemistry Letters

Volumn 4, Issue 2, 2013, Pages 235-238

  Zhang, Yingjie ^a   Yang, Penghui ^a   Chou, C James ^b   Liu, Chunxi ^a   Wang, Xuejian ^c   Xu, Wenfang ^a  

^a SHANDONG UNIVERSITY   (China)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c Postdoctoral Workstation   (China)

Author keywords

histone deacetylases; indole; inhibitor; N hydroxycinnamamide

Indexed keywords

AMIDE; AMINO ACID; HISTONE DEACETYLASE INHIBITOR; INDOLE; N HYDROXYCINNAMAMIDE; UNCLASSIFIED DRUG; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL STRAIN U937; DRUG STRUCTURE; DRUG SYNTHESIS; HELA CELL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; PRIORITY JOURNAL; WESTERN BLOTTING;

EID: 84873975114     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml300366t     Document Type: Article

References (19)

1. Esteller, M. Cancer epigenomics: DNA methylomes and histone-modification maps Nat. Rev. Genet. 2007, 8, 286-298
2. Best, J. D.; Carey, N. Epigenetic opportunities and challenges in cancer Drug Discovery Today 2010, 15, 65-70
3. Witt, O.; Deubzer, H. E.; Milde, T.; Oehme, I. HDAC family: What are the cancer relevant targets? Cancer Lett. 2009, 277, 8-21
4. Gryder, B. E.; Sodji, Q. H.; Oyelere, A. K. Targeted cancer therapy: Giving histone deacetylase inhibitors all they need to succeed Future Med. Chem. 2012, 4, 505-524
5. Giannini, G.; Cabri, W.; Fattorusso, C.; Rodriquez, M. Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives Future Med. Chem. 2012, 4, 1439-60
6. Miller, T. A.; Witter, D. J.; Belvedere, S. Histone deacetylase inhibitors J. Med. Chem. 2003, 46, 5097-5116
7. Paris, M.; Porcelloni, M.; Binaschi, M.; Fattori, D. Histone deacetylase inhibitors: From bench to clinic J. Med. Chem. 2008, 51, 1505-1529
8. DeSimone, R. W.; Currie, K. S.; Mitchell, S. A.; Darrow, J. W.; Pippin, D. A. Privileged structures: Applications in drug discovery Comb. Chem. High Throughput Screening 2004, 7, 473-493
9. Costantino, L.; Barlocco, D. Privileged structures as leads in medicinal chemistry Curr. Med. Chem. 2006, 13, 65-85
10. Kamal, A.; Srikanth, Y. V.; Ramaiah, M. J.; Khan, M. N.; Kashi Reddy, M.; Ashraf, M.; Lavanya, A.; Pushpavalli, S. N.; Pal-Bhadra, M. Synthesis, anticancer activity and apoptosis inducing ability of bisindole linked pyrrolo[2,1-c][1,4]benzodiazepine conjugates Bioorg. Med. Chem. Lett. 2012, 22, 571-578
11. Olsen, C. A.; Montero, A.; Leman, L. J.; Ghadiri, M. R. Macrocyclic Peptoid-Peptide Hybrids as Inhibitors of Class I Histone Deacetylases ACS Med. Chem. Lett. 2012, 3, 749-753
12. Giannini, G.; Marzi, M.; Di Marzo, M.; Battistuzzi, G.; Pezzi, R.; Brunetti, T.; Cabri, W.; Vesci, L.; Pisano, C. Exploring bis-(indolyl)methane moiety as an alternative and innovative CAP group in the design of histone deacetylase (HDAC) inhibitors Bioorg. Med. Chem. Lett. 2009, 19, 2840-2843
13. Attenni, B.; Ontoria, J. M.; Cruz, J. C.; Rowley, M.; Schultz-Fademrecht, C.; Steinkuhler, C.; Jones, P. Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model Bioorg. Med. Chem. Lett. 2009, 19, 3081-3084
14. Lai, M.-J.; Huang, H.-L.; Pan, S.-L.; Liu, Y.-M.; Peng, C.-Y.; Lee, H.-Y.; Yeh, T.-K.; Huang, P.-H.; Teng, C.-M.; Chen, C.-S.; Chuang, H.-Y.; Liou, J.-P. Synthesis and Biological Evaluation of 1-Arylsulfonyl-5-(N- hydroxyacrylamide)indoles as Potent Histone Deacetylase Inhibitors with Antitumor Activity in Vivo J. Med. Chem. 2012, 55, 3777-3791
15. Pontiki, E.; Hadjipavlou-Litina, D. Histone deacetylase inhibitors (HDACIs). Structure-activity relationships: History and new QSAR perspectives Med. Res. Rev. 2012, 32, 1-165
16. Inks, E. S.; Josey, B. J.; Jesinkey, S. R.; Chou, C. J. A novel class of small molecule inhibitors of HDAC6 ACS Chem. Biol. 2012, 7, 331-339
17. Bradner, J. E.; West, N.; Grachan, M. L.; Greenberg, E. F.; Haggarty, S. J.; Warnow, T.; Mazitschek, R. Chemical phylogenetics of histone deacetylases Nat. Chem. Biol. 2010, 6, 238-243
18. Fass, D. M.; Shah, R.; Ghosh, B.; Hennig, K.; Norton, S.; Zhao, W. N.; Reis, S. A.; Klein, P. S.; Mazitschek, R.; Maglathlin, R. L.; Lewis, T. A.; Haggarty, S. J. Short-Chain HDAC Inhibitors Differentially Affect Vertebrate Development and Neuronal Chromatin ACS Med. Chem. Lett. 2011, 2, 39-42
19. Fraga, M. F.; Ballestar, E.; Villar-Garea, A.; Boix-Chornet, M.; Espada, J.; Schotta, G.; Bonaldi, T.; Haydon, C.; Ropero, S.; Petrie, K.; Iyer, N. G.; Perez-Rosado, A.; Calvo, E.; Lopez, J. A.; Cano, A.; Calasanz, M. J.; Colomer, D.; Piris, M. A.; Ahn, N.; Imhof, A.; Caldas, C.; Jenuwein, T.; Esteller, M. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer Nat. Genet. 2005, 37, 391-400